Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2010. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by nine individuals on January 7, 2010, at a price of £12.99 per share. These transactions occurred under the Dividend Reinvestment element of the Company's ShareReward Plan. The specific acquisitions were:
- Mr A P Witty: 25 shares
- Mr J S Heslop: 25 shares
- Mr S M Bicknell: 25 shares
- Mr E J Gray: 25 shares
- Mr S A Hussain: 4 shares
- Mr D Learmouth: 25 shares
- Dr D Pulman: 10 shares
- Mr D S Redfern: 25 shares
- Ms C Thomas: 25 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned share purchases in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of £12.99 per Ordinary share as of January 7, 2010.
- Confirm the total number of shares acquired by the listed directors and managers (194 shares total).
- Review the terms of the ShareReward Plan entered into on October 5, 2001, to understand the Dividend Reinvestment mechanism.